Given that enhanced glycolysis in cancer cells suppresses anti-tumor immunity through metabolic competition with T cells, it is plausible that SIRT7 upregulation in certain malignancies may indirectly promote immune responses by limiting glycolytic flux. This evidence concerns the gene SIRT7 and cancer.